A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database.
about
Management of inflammatory bowel disease in pregnancySafety of TNF-α inhibitors during IBD pregnancy: a systematic reviewManagement of rheumatoid arthritis during pregnancy: challenges and solutionsChallenges and treatment options for rheumatoid arthritis during pregnancy.Biologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Update on biologic safety for patients with psoriasis during pregnancy.Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancySafety of treatment with biologics for psoriasis in daily practice: 5-year data.Automated systems to identify relevant documents in product risk management.The use of anti-TNFα medications for rheumatologic disease in pregnancy.Emerging data on the use of anti-tumor necrosis factor-alpha medications in pregnancy.Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions.Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to knowMaternal death following cardiopulmonary collapse after delivery: amniotic fluid embolism or septic shock due to intrauterine infection?Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature.Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register.Placental TNF-α signaling in illness-induced complications of pregnancy.Rheumatoid arthritis and pregnancy: evolution of disease activity and pathophysiological considerations for drug use.Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study.Placental ischemia-induced increases in brain water content and cerebrovascular permeability: role of TNF-αThe management of rheumatic diseases in pregnancyPregnancy and autoimmune connective tissue diseasesSafety of Tumor Necrosis Factor Inhibitors during Pregnancy and Breastfeeding.Management of inflammatory bowel disease in pregnancy.Pregnancy in glycogen storage disease type Ib: gestational care and report of first successful deliveriesInfliximab in the treatment of rheumatoid arthritisNew and emerging therapies for the treatment of rheumatoid arthritis.Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs.Inflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsiaTherapeutic options for rheumatoid arthritis.Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease.Practical aspects of prescribing a biologic.A safety assessment of tumor necrosis factor antagonists during pregnancy.Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics.Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management.Safety of biologic therapy in rheumatoid arthritis.Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers.Biologics in oral medicine: principles of use and practical considerations.
P2860
Q26865914-8F7FF330-7578-4CAF-9DC6-0F3CB9A1F86DQ27008090-54FCC0B2-24B0-446E-8C40-78CF4826B596Q28068678-8B0D681C-9846-42B2-8793-87121DBEB3B1Q30249730-7FE8271C-F2E9-4E5C-B04A-902012F519D4Q30412650-DC43DEA3-A70E-4BAC-B250-6BED2D224B9CQ33641685-ABC6238B-A8C2-411A-9DE9-F8C05B330014Q33829396-2C3695EB-F62A-40FC-85B4-8072EDDEEFD8Q33854744-879755D4-F56C-4415-AFF9-04ED62127C0BQ34180297-3DC25EA6-0278-4D80-8197-960128F2C249Q34272138-A3A1D850-11E6-408C-96C2-8E636B993898Q34333931-F22C2CD0-FDAC-45D3-971A-3AD7B726080DQ34385326-3AFE3825-343A-4BF8-985B-D39541E8C053Q34389362-B79F7115-466C-413F-A955-A89A765722C6Q34494722-00385656-50E4-4C17-AC11-76DE2AB90482Q34620323-B34455D4-5B10-425F-9697-F67FA71189C3Q34758793-6D681A79-58AE-4B49-A747-9F6BB79A3A1EQ35071279-005AAA6E-D171-491A-B73C-E1642304B4ABQ35415687-36232E1B-F745-478E-A112-EC7B156E652EQ36125487-94BD21A7-EF92-411E-8F53-FBEEEA7D6A3CQ36422506-64984883-7A93-48E1-B7DA-0286D6B00B40Q37047839-1F434F65-9969-4F3E-8E0D-5C54ECD8D2C1Q37100267-3CC70095-1A1B-4466-93ED-922CC22AF83AQ37149381-54733683-5130-4C29-9A3B-301219A2105CQ37186177-CE200DF0-EC8A-44EB-BF95-045D8D1DD462Q37238915-AC681B82-C735-4992-B0F9-CAE32B039B28Q37303230-08159084-4C57-46EE-B081-ABB21FCE93D2Q37358229-454CEAFE-8112-4B50-BE05-218B45F12614Q37390458-513BCF52-A19E-42A3-BA01-47F3E2FBB3D5Q37483133-2337FD59-5168-43AF-BB44-47408DA8A745Q37552947-1950CF88-6CC4-42C7-9B36-1827A5FEBA98Q37554366-7631FC4F-BFCB-4E8D-8D70-23E8DCF9ACDEQ37607426-C41E74F1-51E2-475B-A448-184FA4686AD9Q37724349-06FBE817-7A50-4822-A735-64891E2E8D49Q37738882-4B5F778F-8CFA-41C5-ABC1-A7D09F3028ADQ37814549-F5675E73-77C8-4B02-8C27-111899350ABCQ37820898-6A008094-FFCD-4393-8620-AA25880CE144Q37943826-BC9660BB-3CF6-41EF-A812-11A4FB281CE6Q37944433-1970547B-7E11-49DB-8170-840FEAF24D4AQ37991751-78578F0F-5975-4F7B-AB25-865FE13CA744Q37993932-B5D870D5-07CA-445A-A5C0-D52CEB026FBA
P2860
A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A safety assessment of tumor n ...... Drug Administration database.
@en
A safety assessment of tumor n ...... Drug Administration database.
@nl
type
label
A safety assessment of tumor n ...... Drug Administration database.
@en
A safety assessment of tumor n ...... Drug Administration database.
@nl
prefLabel
A safety assessment of tumor n ...... Drug Administration database.
@en
A safety assessment of tumor n ...... Drug Administration database.
@nl
P2093
P356
P1476
A safety assessment of tumor n ...... Drug Administration database.
@en
P2093
Anil Ladhani
Frank B Vasey
Joanne Valeriano
John D Carter
Louis R Ricca
P304
P356
10.3899/JRHEUM.080545
P407
P577
2009-03-01T00:00:00Z